2 hours BridgeBio Pharma (NASDAQ:BBIO) Stock Rating Reaffirmed by HC Wainwright MarketBeat
HC Wainwright reaffirmed a “buy” rating and issued a $43.00 target price on shares of BridgeBio Pharma in a report on Monday.
HC Wainwright reaffirmed a “buy” rating and issued a $43.00 target price on shares of BridgeBio Pharma in a report on Monday.